FDA approves first generic liraglutide injection for Type 2 diabetes treatment

Pallavi Madhiraju- December 24, 2024 0

In a significant milestone for diabetes care, the U.S. Food and Drug Administration (FDA) has approved the first generic equivalent of liraglutide injection, a glucagon-like ... Read More

Indoco Remedies secures FDA tentative approval for Canagliflozin Tablets

Pallavi Madhiraju- December 6, 2023 0

Indoco Remedies Ltd., a renowned player in the global pharmaceutical industry, has announced receiving tentative approval from the United States Food and Drug Administration (USFDA) ... Read More

Pfizer’s danuglipron shows promising results in Phase 2b obesity trial

Pallavi Madhiraju- December 3, 2023 0

Pfizer Inc. (NYSE: PFE) has announced encouraging topline data from its Phase 2b clinical trial (NCT04707313) investigating danuglipron, an oral Glucagon-like peptide-1 receptor agonist (GLP-1RA), ... Read More

Lilly bags Zepbound FDA approval for obesity treatment

Pallavi Madhiraju- November 9, 2023 0

The U.S. Food and Drug Administration has granted approval to Eli Lilly's Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP ... Read More

FDA approves ZITUVIMET by Zydus Lifesciences for Type 2 diabetes treatment

Pallavi Madhiraju- November 6, 2023 0

Zydus Lifesciences Limited has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for ZITUVIMET, a combination of Sitagliptin and ... Read More

Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal

Pallavi Madhiraju- October 7, 2023 0

Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada's esteemed specialty pharmaceutical giant. This ... Read More

Novo Nordisk acquires Embark Biotech and enters R&D collaboration to advance obesity treatments

Pallavi Madhiraju- August 30, 2023 0

Novo Nordisk, a global leader in healthcare, has acquired Embark Biotech, including its lead metabolic program, in a deal that further strengthens its portfolio in ... Read More

Lupin acquires diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim

Pallavi Madhiraju- August 19, 2023 0

In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ... Read More

BRENZAVVY proves effective in TheracosBio’s Phase 3 Type 2 diabetes study

Pallavi Madhiraju- August 4, 2023 0

TheracosBio announced the publication of a 24-week randomized, double-blind, placebo-controlled trial, proving Bexagliflozin's effectiveness as an adjunct to Metformin for treating adults with type 2 ... Read More

Eli Lilly’s Tirzepatide triumphs in Phase 3 weight loss studies

Pallavi Madhiraju- July 27, 2023 0

Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related ... Read More